Article
Pharmacology & Pharmacy
Firas Almasri, Emmanuel H. Sakarya, Raffi Karshafian
Summary: This study demonstrates the potential of combining chemotherapy and therapeutic ultrasound-microbubble treatment to enhance radiotherapy in inducing cell death and apoptosis, as well as long-term tumor shrinkage, in an in vivo cancer model.
Article
Biology
Kevin J. Tu, Sanjit K. Roy, Zachery Keepers, Manas R. Gartia, Hem D. Shukla, Nrusingh C. Biswal
Summary: The study investigates the effectiveness and molecular characteristics of the combination therapy of Docetaxel (DXL) and radiation in vitro. The results suggest that DXL sensitizes castration-resistant prostate cancer (CRPC) cells to radiation by downregulating CAV-1.
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Daniel Wegener, Daniel M. Aebersold, Marc-Oliver Grimm, Peter Hammerer, Michael Froehner, Markus Graefen, Dirk Boehmer, Daniel Zips, Thomas Wiegel
Summary: The results of three randomized clinical trials comparing adjuvant radiotherapy (ART) and early salvage radiotherapy (eSRT) for prostate carcinoma were recently published. The findings suggest that early eSRT is as effective and potentially less toxic than ART. Therefore, eSRT should be considered the standard of care. However, ART remains a valid treatment option for patients with high-risk features.
Article
Oncology
Ioulia Vardaki, Paul Corn, Emanuela Gentile, Jian H. Song, Namrata Madan, Anh Hoang, Nila Parikh, Leah Guerra, Yu-Chen Lee, Song-Chang Lin, Guoyu Yu, Elmer Santos, Marites P. Melancon, Patricia Troncoso, Nora Navone, Gary E. Gallick, Eleni Efstathiou, Sumit K. Subudhi, Sue-Hwa Lin, Christopher J. Logothetis, Theocharis Panaretakis
Summary: The study found specific molecular differences in exosomes under Radium-223 treatment that may reflect the overall survival of patients, suggesting potential for monitoring treatment response. Furthermore, immune-suppressors related to the efficacy of Radium-223 were detected in exosomal transcripts from patients, indicating the potential of ICT to enhance the efficacy of Radium-223.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Lukas Donix, Holger H. H. Erb, Claudia Peitzsch, Anna Dubrovska, Manuel Pfeifer, Christian Thomas, Susanne Fuessel, Kati Erdmann
Summary: This study aimed to investigate the influence of acquired resistance against ionizing radiation or docetaxel chemotherapy on cisplatin tolerance in metastatic castration-resistant prostate cancer (mCRPC) cell line models. The results indicate that previous radiotherapy may moderate sensitization to cisplatin, while docetaxel resistance does not affect cisplatin tolerance. Different mCRPC cell lines exhibit significant variability regarding cisplatin tolerance.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2022)
Article
Pharmacology & Pharmacy
Thiago S. Lima, Luciano O. Souza, Diego Iglesias-Gato, Johanna Elversang, Flemming Steen Jorgensen, Tuula Kallunki, Martin A. Roder, Klaus Brasso, Jose M. A. Moreira
Summary: Itraconazole can re-sensitize docetaxel-resistant prostate and breast cancer cells by binding to ABC transporter protein ABCB1, inhibiting the transport of docetaxel.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Oncology
Siven Chinniah, Bradley Stish, Brian A. Costello, Lance Pagliaro, Daniel Childs, Fernando Quevedo, Fabrice Lucien, Alan Bryce, Sean S. Park, Jacob J. Orme
Summary: The review examines the evidence for localized RT in the presence of oligometastatic disease and metastasis-directed therapy in both hormone-sensitive and hormone-resistant prostate cancer. It also outlines the potential future incorporation of RT as immune-sensitizing therapy and the importance of highly sensitive imaging modalities in considering RT in metastatic disease.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)
Article
Oncology
Haoli Yin, Haixiang Qin, Lei Yang, Mengxia Chen, Yang Yang, Wenlong Zhang, Jiange Hao, Qun Lu, Jingyan Shi, Junlong Zhuang, Xuefeng Qiu, Hongqian Guo
Summary: This study found that circCYP24A1 was upregulated in DTX-resistant PCa cells and promoted DTX resistance by suppressing chemosensitivity and regulating ALDH1A3 expression. Further research revealed that circCYP24A1 functioned by sponging miR-1301-3p and activating the PI3K/AKT/mTOR signaling pathway. Statistical analysis identified circCYP24A1 as an independent risk factor for predicting DTX response.
BIOMARKER RESEARCH
(2022)
Review
Oncology
Gert De Meerleer, Charlien Berghen, Alberto Briganti, Christof Vulsteke, Julia Murray, Steven Joniau, Anne M. Leliveld, Cesare Cozzarini, Karel Decaestecker, Kato Rans, Valerie Fonteyne, Olivier De Hertogh, Alberto Bossi
Summary: The use of elective whole pelvis radiotherapy in prostate cancer patients with a high risk of pelvic nodal disease remains controversial. In certain patient populations, combining whole pelvis radiotherapy with androgen deprivation therapy may significantly improve survival rates. The utilization of modern radiotherapy technology can reduce the risk of severe late urinary and intestinal toxic effects.
Article
Oncology
Laurence Booth, Jane L. Roberts, Cameron West, Paul Dent
Summary: GZ17-6.02 and olaparib interact to kill prostate cancer cells by increasing autophagy and enhancing endoplasmic reticulum stress signaling. In vivo, GZ17-6.02 as a single agent significantly reduced tumor growth.
FRONTIERS IN ONCOLOGY
(2022)
Review
Medicine, General & Internal
Shahneen Sandhu, Caroline M. Moore, Edmund Chiong, Himisha Beltran, Robert G. Bristow, Scott G. Williams
Summary: Management of prostate cancer is rapidly evolving with advances in understanding the genomic landscape, improved imaging methods, and personalised therapeutics targeting DNA repair pathways. The therapeutic framework for metastatic disease has shifted, with oligometastatic disease being evaluated for metastatic-directed therapies, and novel androgen pathway inhibitors showing significant survival benefits as first-line therapy for metastatic disease. Emerging research into molecular characterisation and novel therapeutics, such as targeted radioisotopes and immunotherapy, hold promise for improving patient outcomes.
Review
Medicine, General & Internal
Liam King, Nijole Bernaitis, David Christie, Russ Chess-Williams, Donna Sellers, Catherine McDermott, Wendy Dare, Shailendra Anoopkumar-Dukie
Summary: Prostate cancer is the second most commonly diagnosed cancer worldwide, and the development of radioresistance is a major challenge in treatment. Understanding the biological mechanisms behind radioresistance is crucial for developing effective therapies.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Medicine, Research & Experimental
Zehua Ma, Weiwei Zhang, Baijun Dong, Zhixiang Xin, Yiyi Ji, Ruopeng Su, Kai Shen, Jiahua Pan, Qi Wang, Wei Xue
Summary: This study found that docetaxel-based chemohormonal therapy activates the immune response in prostate cancer and facilitates T cell infiltration, thereby improving the efficacy of anti-PD1 blockade therapy.
Article
Oncology
Steven P. Zielske, Wei Chen, Kristina G. Ibrahim, Frank C. Cackowski
Summary: This study explored the role of a long non-coding RNA (lncRNA), SNHG1, in prostate cancer biology. It found that SNHG1 is associated with cell proliferation, quiescence, and sensitivity to docetaxel.
Article
Oncology
Stefano Martellucci, Letizia Clementi, Samantha Sabetta, Paola Muzi, Vincenzo Mattei, Mauro Bologna, Adriano Angelucci
Summary: Human tau is a multifunctional protein involved in microtubule turnover, and tau oligomers are pathologic forms associated with protein accumulation diseases. In prostate cancer cells, autophagy inhibition led to tau oligomers accumulation and increased cytotoxic effect by docetaxel, indicating a potential role of autophagy in cancer growth and chemotherapy response. Therapeutic strategies targeting tau oligomers formation, such as autophagy inhibition, could be effective in cancer therapy.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2021)